Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6467993

COc1cc2nc(Nc3nc(O)c4cc(OCCN5CCOCC5)ccc4n3)nc(O)c2cc1OC.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 4/20 0.47
FGFR2 P21802 1/20 0.46
RET P07949 1/20 0.45
EGFR P00533 6/20 0.45
MAP2K1 Q02750 1/20 0.44
SIK2 Q9H0K1 1/20 0.44
SIK3 Q9Y2K2 1/20 0.44
SRC P12931 1/20 0.44
KDR P35968 2/20 0.43
AVPR1B P47901 1/20 0.43
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6467998 0.92 RAF1 (0.43) RAF1FGFR2RETEGFRMAP2K1
Trifluoroacetic Acid SCHEMBL6469150 0.89 RET (0.42) RAF1RETEGFRKDRAVPR1B
Trifluoroacetic Acid SCHEMBL6471240 0.88 RET (0.43) RAF1RETEGFRSRCKDR
Trifluoroacetic Acid SCHEMBL6469209 0.88 RET (0.43) RETEGFRKDRAVPR1BPDGFRB
Trifluoroacetic Acid SCHEMBL6469939 0.88 AVPR1B (0.43) RAF1SIK2SIK3AVPR1B
Trifluoroacetic Acid SCHEMBL6469649 0.88 RAF1 (0.39) RAF1RETAVPR1B
Trifluoroacetic Acid SCHEMBL6470128 0.87 PDK1 (0.41) RAF1RETAVPR1B
Trifluoroacetic Acid SCHEMBL6468017 0.85 HSD17B10 (0.40) RAF1RETKDRAVPR1B
Trifluoroacetic Acid SCHEMBL6468678 0.85 HRH3 (0.46) RETAVPR1B
Trifluoroacetic Acid SCHEMBL6469205 0.84 KDM4E (0.36) RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB RAF1 2421/4885FGFR2 4843/4885RET 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.